Thank our our successful a Senseonics on each detail. I'll followed you, performance, Today's measures Ascensia update some Eversense's XXXX all our we'll was progress then And the initiatives. Chief programs strategic Financial the including the in financials for we growth Officer, across product questions.
XXXX as our advance us pipeline. Trip, strategic on Then highlights Senseonics' of solid initiatives business discuss open to quarter Rick an performance. by of in Sullivan, joining you will made fourth will year call for Senseonics support up start call commercial ongoing and an providing also update thank by provide to this afternoon. on strengthening for development
subsequent FDA clinical supporting front, our for Eversense ENHANCE data over the campaign. XXX% patients for impressions we expanded the imminent increase system. designation. an as UnitedHealthcare coverage filed for to And clinical advertising from we submission Medicare. submission direct-to-consumer market in and access And result expanded trial regulatory On XXX-day the by and of analysis securing awareness iCGM ADC's notably website We the we our millions completed with of a of and
indications revenue liquidity our see year expansion sheet position. We the commercial year strengthened of also milestones, gained a regulatory catalysts plan guidance our strategic another development towards in full We payers.
Financially, through we key delivering increasing significant reducing work of and as and achieved we XXXX other initiatives. our our debt balance across basal-only progress number by and for expansion patient growth approvals, across as hypoglycemic our
and totaled revenue as revenue million compared awareness sales XXXX, representing access of prior revenue $X quarter for the the In compared our million XXXX, million.
Through of year totaled period, and has to and fourth representing XX% full the the collaboration for million $XX.X quarter, sales total adoption our U.S., increase prior generated $X.X $X.X Eversense achieved For to we total market. fourth the in Senseonics generated to agreement, growth guidance and drive of the year the to growth Ascensia year outside U.S. period. XX% responsibility
patient increased and base X,XXX Eversense nearly XX% increase to notably and year-over-year. did of new In short the awareness approximately expectation. fell U.S. While patient access than Ascensia's the product in our both and to XXXX, XXXX, XX% users insertions improved of more
importance performance. greater a improve Eversense believe results.
We However, to drive and received with this of support the strengthening order growth, recognize, for of positive in potential we commercial together Eversense the commercial the believe dynamics further holds set Ascensia, will stronger
of changes easier, network their build-out for together CGM-focused by and by team, in of to insertion. campaign, in wins to that make leads Ascensia's payer with in removable key Eversense, benefits and of further strong exceptional place broader continue know organizational features having and supported marketing highlights such year, full Xx, for is importantly, establishment subsequent from benefits of of available, a campaign this figures, XXXX the the are the as with the predictive commercial access hires, Most UnitedHealthcare, patient a to accuracy, inserter the user with the the as mid-XX% success Eversense take by this many the in seeing product. the launched of Not which that improve them also unique retention rates This high. of view we of was retention the rates longest-lasting our increased CGM range. and remains number strongly those are geographies, benefits.
With potential that direct-to-consumer each transmitter sensor the resonating October. more adoption.
Encouragingly, patient on-body key but see of Eversense We we alerts Eversense's demand validation only And our positions advantage retention In patients. the interest
and included investment health meaningful a discussed As the last marketing care for was launched ADC this that This commercials, Eversense. television new we patients social among ad professionals. in integrated awareness on quarterly expanded call, creative new to build and direct-to-consumer campaign media,
With than Eversense. a patient the unique to see campaign benefits in patient increase enthusiasm stronger response and pleased better are that we was to the of very leads, the expected, articulate
and ADC's in execution. implantable demonstrated processes, limiting to on the the inside ability for effectively leads. sales Lead increase generation demand lead strategy, and right the clearly further critical our CGM, is having significant While resources of relies leads their commercial infrastructure conversion influx the validated convert stressed and and
take lead approach, will is leadership expect and we efforts the their latent and that these conversion currently to new demand them for campaign and Ascensia's Eversense of redesigning their enable direct-to-consumer advantage bolstering built. new
XXXX. not were lower Ascensia will impact orders inventory accumulated in that was conversion quarter of has demand placed, us their increased purchases from the first projected half by the that that was given However, fourth when offset
expect to As implement going CGM forward. see and functions Ascensia improved strengthen these dedicated continues measures to commercial several we the to commercial infrastructure, enhance conversions
revolutionary point, clearly separated growth, will has provide positive helped leading developed. we that unit business. improve current system. collaboration. primed for we going priority launch of advance responsibility step, planned Brian we commercial revenue insulin of our of built business being in has channel. the believe competitive for a towards excited commercial be one with look acceleration.
To now from and focus industry Diabetes the CGM PHC Officer leadership into CGM CGM leadership CGM experience him independent strategy performance driving efforts. updated and its previously overcoming Commercial phase recently we will Care, plan will dedicated pump a market. monitoring of important This reporting we business. this the be innovative tenfold revenue working durable leadership and unit products, very the XXX-day transition, within for for the XXXX of strength to created next are his reviewed, and a Brian is a appointed for blood the additional strategies equipment We're After this veteran, and execution were an announce into growth Ascensia, new continuing successfully as ensure a is to is worldwide full He challenges thrilled commercial addition to are President the with served our leveraging the Eversense highly leader the unit glucose forward medical and company He The forward complex contributions.
With to Eversense and Brian these we with commercial business was Chief for has and reputation PHC transform Tandem to the collaborate forward.
Together, to business very the be look directly driving launching to resources in his Hansen, top The as to growth where valuable that within
to submit XXX-day timing experienced. of the new of of are appointment, that coming April, approval this improvement timing given in today, for current lower begins first will ADC's the to patient FDA the initiatives, the and continue to product we Considering Brian's year. the base, in half the approval plan that fiscal this first year, the half product, actual mind the the weeks conversion dynamics, year-end than they patient the and expect We inventory in be in and uncertainty review for in purchases sales inherent recent launch year. shortfall which for conversion launch our platform outlook Keeping their providing Ascensia of the and
the growing, Ascensia XXX% in New XXXX, to within number grow first patient the just half XXXX sales the and in starts over to of total sales of half. patient is new exceed pace year-over-year on expected with are first new patient
half net to of commercial growth dynamics. our quarter As XXXX. result, outlook million, global first more our plan a we timing XX% in expect first of analysis of revenue half of second launch XXXX $XX We to approximately full refined initiatives the and a over a the following comprehensive current of year and the provide approximately product view Senseonics' be representing
turn growing demand. region. the Italy periods, the base Germany, year new win the ended in Consistent we CGM QX, continued. ADC and other and efforts sales as in In geographies $X.X user prior stabilized to channel further expected U.S., now can in million. builds support that with future, future we appears its continue of the Outside out Ascensia as In and to to them in growth the coverage with expect to Europe, patient growth has it tenders the
Now care like expand focused to particularly updates provider initiatives, health access I our strategic and experience. growth would on provide streamlined to efforts our patient on
workflow options access convenient designed is The providers. for expanding Eversense fastest-growing of insertion network, is consists this Eversense network X patients. type Our streamlined strategy, inserter our for diabetes and of a more component certified for in more patients instrumental key an to providers, segment, a provide which sensor
are to need on the to care allows it's diabetes, benefits As Eversense X training. insertion we base. of without opposed type also the treated options educating offices type focus It vast insertion endocrinology user X force of important sales increasing health patients outside on Ascensia clinical providers majority the the as that for the of with expand
year. experience one MPG with ever When the XX-day the we underway. driver the expansion partnership get reducing network XXX MPG required that to well number in XXX significant improving we quarter, strategy patient continuing insertions their of year insertions the plan from was to been extend do thereby two-pronged a cut XX% Eversense. to a Our insertions to to this parallel, the of strategic longevity than it per the receiving of that sensor through easier with users half. is build again of make sensor.
In in fourth patients days, via Part the network for is the the per of year has number inserter to we with are sensor, the move We
over professional make the we strong As converge, in confident office readily per progress self-remove will one lieu accept we XX-minute day, and times to procedure to sensors reinsert continue local insertion end. of towards manually having year. are XX arms X patients that Every that
front. Moving on access the to
the Meridian, and as of just the payers risk coverage We that to multiple encouraged MACs government with of recently value patients are Medicare published implantable the use commercial recognition final that local daily diabetes patients determinations MDI of from both all These contractors: range those well by insulin, than X Medicare broader CGM announced by expanded extend on administrative as hypoglycemia. NGS. removing We Medicare including restriction brings who and by have and the coverage coverage CGMs individuals Palmetto at for injections. noninsulin-taking
are in total typically is insulin double Eversense. hypoglycemic we indications, case, with the that use these for follow We also seeing suit As policy. coverage market effectively commercial X CMS's payers new estimate expanded risk, addressable the basal
and cell sensor insertion, population. Medicare for anticipate patients, this unique as that product's the within serve a safety vibration for we long our on-body for professional eliminates secondary such population strong adoption mechanism as Given placement, advantages life need Medicare the sensor which expanded alerts
see transmitter are type prioritize sensors and who additional every and convenience remaining to flexibility type offers able Xs CGM.
Throughout policy representing These anticipate segment, to will our of for patients and commercial key contributing growth. fueling implantable typically now to further new for factors XXXX, over XX X our sensors replace simplicity, the adopt and MAC similar not of Eversense. decisions Eversense we need needed, being recent penetration of to which remove worry awareness we an fastest-growing policies, falling to the payers off, Moreover, about further days, being having patient not XX% XX frequently having the the advantages validate as
with discussions These in and engaging CGM of patient care populations, their Eversense simultaneously an accountable reducing risk who managing recognize the integrate is assume a organization. as effective actively pathways for are we systems means There outcomes care to ahead, health while large organizations, into provider influence health patient costs. opportunity and to improve their leverage substantial these care health offices. over Looking systems directly
weekly or compared recognize product us long-term to providing high turnover of Given while are diabetes implanted achieve positive transcutaneous sensors, an of adherence patients to overall to potential required reduced comes systems biweekly the system from with their quality the beginning care. to inherent that a the by ROI their for agreements, the cost improved measures the and a value-based outcomes supporting the important simultaneously health help
scalable commercial data assistance ACOs forward.
To moves by savings joining of been simple proposition XXXX. Ascensia's the commitment payment as their Beyond efforts, goal close and to offering growth a a is solution, ground-level program health showcase the the and has designed team out support evidenced and going the the unlimited diabetes is the investments product, discussions, to Ascensia combining intelligence a to This of Brian is compelling commercial the announcement and Senseonics making extending systems. being in systems out population to management comprehensive with value prove model services to and to health working Hansen
iCGM market a implantable in CGM the and aware, a the doubling through challenges Eversense important as work strategy, expand, are and development signals new exciting ADC to working our we by energized the still with make them the patients, and we for growth The groundwork being are submission all systems our continue effectively systems.
Together with elements pipeline aggressively an essential of for as focused care. decision. for remains provided to a we laying research, play in have the collaboration side but long-term disruptor, of we we from we on the the to to business manufacture on our all our areas Ascensia, lot of necessary our more are that Furthermore, payers that designation opportunity with such has of the to with achieve health and health partnership innovation believe milestones. and agency, address role continues with that course, in you as of responsibilities is indications, Eversense. review with we product.
Advancing the products, at innovation As come active while Senseonics' Starting information expanded do, are remaining providers, have market of make to forefront improving the and diabetes commercial new strides
more strategy and is to using are the providing importantly, diabetes other more approximately for with additional delivery for forward the here essential, patients and, who Integration insulin steps important technologies year company. next benefits X to the look providing automated iCGM We updates currently Senseonics devices. this million are
fourth in out Looking the we slightly approval quarters, next-generation to XXX-day plan for continue our coming further for system quarter. in the
the technology sensor diabetes in that several management for differentiators Eversense the our completion the an the year and clinical major reduction preparing of differentiated a advancement data in full belief single study in submission stages represent a an final upon a the market. With for and point review, in frequency. protection will a FDA of Eversense submit, with we offer These system calibration system.
We of from plan CGM, will XXX-day of to the our are U.S. and approval the the basis significant iCGM anticipate XXX-day and ENHANCE implantable of pivotal are benefits inflection an system
with goal work we in of target securing system, for the months XXXX. with submission, X-year FDA, of approval we X quarter the the the launch Eversense planned continue after fourth the approximately its to As
generation of self-powered the system Gemini removing with transmitter. XXX-day any the addition, ultimate for for products goal the of platform and basis subsequent the the development is on-body the also In Freedom need
turn step review excited half for CGM financials. to technology.
With Gemini another Gemini that, for XXXX. the vision of forward I'll of Rick in first-in-human our represents a call are over of the We in now the This testing for massive second
